share_log

上海医药(601607.SH):注射用帕瑞昔布钠新增规格获得批准文号

Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved

Gelonghui Finance ·  Apr 30 06:36

Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment